Vancomycin 1.25-1.50% in a complex gel formulation trademarked Vancogel(R) for Bacterial Infections

Phase-Based Progress Estimates
1
Effectiveness
2
Safety
Bacterial Infections+1 More
Vancomycin 1.25-1.50% in a complex gel formulation trademarked Vancogel(R) - Drug
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This trial is testing whether Vancomycin can help heal open wounds by eliminating MRSA.

Eligible Conditions
  • Bacterial Infections
  • wound site

Treatment Effectiveness

Study Objectives

1 Primary · 1 Secondary · Reporting Duration: 3 weeks

3 weeks
More rapid healing of cSSTI
One week
Eliminate MRSA infection

Trial Safety

Safety Progress

2 of 3
This is further along than 68% of similar trials

Trial Design

2 Treatment Groups

Drug Vancogel,Treatment,Kill MRSA,Heal
1 of 2
Placebo
1 of 2
Experimental Treatment
Non-Treatment Group

100 Total Participants · 2 Treatment Groups

Primary Treatment: Vancomycin 1.25-1.50% in a complex gel formulation trademarked Vancogel(R) · Has Placebo Group · Phase 2

Drug Vancogel,Treatment,Kill MRSA,Heal
Drug
Experimental Group · 1 Intervention: Vancomycin 1.25-1.50% in a complex gel formulation trademarked Vancogel(R) · Intervention Types: Drug
Placebo
Drug
PlaceboComparator Group · 1 Intervention: Placebo, complex gel formulation without Vancomycin · Intervention Types: Drug

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: 3 weeks

Who is running the clinical trial?

Robert S Berman MDLead Sponsor
Robert S Berman, MDPrincipal Investigator - undefined
Jupiter Medical Center
University Of Kansas School Of Medicine (Medical School)
Vet Affairs Medical Ctr-W La (Residency)

Eligibility Criteria

Age 18+ · All Participants · 9 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 21st, 2021

Last Reviewed: October 11th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.